The news is directly about Sage Therapeutics. Goldman Sachs, a major financial institution, has maintained a Neutral rating on the company, indicating no major changes in the company's performance. However, the increase in price target from $22 to $25 suggests a positive outlook, which could potentially influence investor sentiment and the stock's performance in the short term.